康艾注射液联合化疗治疗晚期非小细胞肺癌的有效性与安全性研究

The Clinical Research into Efficiency and Safety of Kang'ai Injection Combined with Chemotherapy in Treatment of Advanced Non-Small Cell Lung Cancer

目的:观察康艾注射液联合化疗治疗晚期非小细胞肺癌的临床疗效与安全性。方法:将40例晚期非小细胞肺癌患者随机分为对照组和治疗组各20例,对照组采用单纯放疗治疗,至少化疗2周期,治疗组采用康艾注射液联合化疗治疗,观察两组患者的近期疗效及不良反应发生情况,并对患者生活质量进行KPS评分。结果:治疗后,治疗组与对照组近期疗效比较,治疗组优于对照组,差异有统计学意义(P<0.05);两组患者KPS评分比较,治疗组患者生活质量改善情况优于对照组,差异有统计学意义(P<0.05);两组患者不良反应发生率比较,治疗组低于对照组,差异有统计学意义(P<0.05)。结论:康艾注射液联合化疗治疗非小细胞肺癌有助于提高患者生存时间,降低不良反应发生率,提高患者生活质量。

Objective： To observe efficiency and safety of Kang＇ai Injection combined with chemotherapy in treatment of advanced non-small cell lung cancer. Methods： Forty patients with advanced non-small cell lung cancer were randomly divided into the control group and the treatment group,with 20 cases in each group. The ones in the control group were given only chemotherapy for at least 2 courses,while the ones in the treatment group were added Kang＇ai Injection based on the treatment of the control group.Then the short-term efficacy and adverse reactions of the two groups were observed,and the qualities of life of patients were given KPS score. Results： After the treatment,in terms of the short-term efficacy,the treatment group was better than the control group,and the difference between them had statistical significance（ P〈0. 05）. In terms of KPS score,the quality of life was improved better than that of the control group,and the difference was statistically significant（ P〈0. 05）. In terms of adverse reaction incidence,the treatment group was lower than the control group,and the difference was statistically significant（ P〈0. 05）. Conclusion： Kang＇ai Injection combined with chemotherapy in treatment of advanced non-small cell lung cancer can improve the survival time of patients,reduce the incidence of adverse reactions and improve the quality of life of patients.